194 related articles for article (PubMed ID: 12637126)
1. Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia.
Duetz MS; Schneeweiss S; Maclure M; Abel T; Glynn RJ; Soumerai SB
Clin Ther; 2003 Jan; 25(1):273-84. PubMed ID: 12637126
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
Schneeweiss S; Walker AM; Glynn RJ; Maclure M; Dormuth C; Soumerai SB
N Engl J Med; 2002 Mar; 346(11):822-9. PubMed ID: 11893794
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.
Schneeweiss S; Soumerai SB; Maclure M; Dormuth C; Walker AM; Glynn RJ
Clin Pharmacol Ther; 2003 Oct; 74(4):388-400. PubMed ID: 14534526
[TBL] [Abstract][Full Text] [Related]
4. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.
Schneeweiss S; Soumerai SB; Glynn RJ; Maclure M; Dormuth C; Walker AM
CMAJ; 2002 Mar; 166(6):737-45. PubMed ID: 11944760
[TBL] [Abstract][Full Text] [Related]
5. Physician and Patient Adjustment to Reference Pricing for Drugs.
Robinson JC; Whaley C; Brown TT; Dhruva SS
JAMA Netw Open; 2020 Feb; 3(2):e1920544. PubMed ID: 32022881
[TBL] [Abstract][Full Text] [Related]
6. Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents.
Schneeweiss S; Dormuth C; Grootendorst P; Soumerai SB; Maclure M
Med Care; 2004 Jul; 42(7):653-60. PubMed ID: 15213490
[TBL] [Abstract][Full Text] [Related]
7. The Impact of reference pricing on prescribing patterns, costs, and health services utilization of proton pump inhibitors: A quasi-experimental study in British Columbia, Canada.
Au SW; Law MR; Cheng L; McGrail K; Harrison M
Health Policy; 2024 Jun; 144():105061. PubMed ID: 38676977
[TBL] [Abstract][Full Text] [Related]
8. Prescription duration after drug copay changes in older people: methodological aspects.
Schneeweiss S; Maclure M; Soumerai SB
J Am Geriatr Soc; 2002 Mar; 50(3):521-5. PubMed ID: 11943050
[TBL] [Abstract][Full Text] [Related]
9. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA.
Mintzes B; Barer ML; Kravitz RL; Bassett K; Lexchin J; Kazanjian A; Evans RG; Pan R; Marion SA
CMAJ; 2003 Sep; 169(5):405-12. PubMed ID: 12952801
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.
DeJong C; Aguilar T; Tseng CW; Lin GA; Boscardin WJ; Dudley RA
JAMA Intern Med; 2016 Aug; 176(8):1114-1122. PubMed ID: 27322350
[TBL] [Abstract][Full Text] [Related]
11. Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available.
Wladysiuk M; Araszkiewicz A; Godman B; Szabert K; Barbui C; Haycox A
Appl Health Econ Health Policy; 2011 Mar; 9(2):101-10. PubMed ID: 21271749
[TBL] [Abstract][Full Text] [Related]
12. Physician gender and antihypertensive prescription pattern in primary care.
Sequeira RP; Al Khaja KA; Damanhori AH; Mathur VS
J Eval Clin Pract; 2003 Nov; 9(4):409-15. PubMed ID: 14758963
[TBL] [Abstract][Full Text] [Related]
13. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of vaginal antifungal products.
Gurwitz JH; McLaughlin TJ; Fish LS
Health Serv Res; 1995 Dec; 30(5):672-85. PubMed ID: 8537226
[TBL] [Abstract][Full Text] [Related]
14. Prescribing and drug costs in the province of Ontario.
Lexchin J
Int J Health Serv; 1992; 22(3):471-87. PubMed ID: 1644510
[TBL] [Abstract][Full Text] [Related]
15. Does knowledge of medication prices predict physicians' support for cost effective prescribing policies.
Polinski JM; Maclure M; Marshall B; Cassels A; Agnew-Blais J; Patrick AR; Schneeweiss S
Can J Clin Pharmacol; 2008; 15(2):e286-94. PubMed ID: 18641423
[TBL] [Abstract][Full Text] [Related]
16. Payments from drug companies to physicians are associated with higher volume and more expensive opioid analgesic prescribing.
Zezza MA; Bachhuber MA
PLoS One; 2018; 13(12):e0209383. PubMed ID: 30566426
[TBL] [Abstract][Full Text] [Related]
17. Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage.
Cadarette SM; Carney G; Baek D; Gunraj N; Paterson JM; Dormuth CR
Osteoporos Int; 2012 Apr; 23(4):1475-80. PubMed ID: 21901476
[TBL] [Abstract][Full Text] [Related]
18. Physician Perceptions of Step Therapy Prescribing Requirements.
Fischer MA; Kesselheim AS; Lu Z; Ross KM; Tessema FA; Avorn J
J Manag Care Spec Pharm; 2019 Nov; 25(11):1210-1224. PubMed ID: 31663459
[TBL] [Abstract][Full Text] [Related]
19. Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors.
Bourgault C; Elstein E; Le Lorier J; Suissa S
CMAJ; 1999 Aug; 161(3):255-60. PubMed ID: 10463046
[TBL] [Abstract][Full Text] [Related]
20. Health services utilization with reference drug pricing of histamine(2) receptor antagonists in British Columbia elderly.
Hazlet TK; Blough DK
Med Care; 2002 Aug; 40(8):640-9. PubMed ID: 12187178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
